ACADIA PHARMACEUTICALS INC. 2023-2024 Proxy Voting Records

Description as filed by funds: To elect three Class II directors to hold office until the Company's 2027 Annual Meeting of Stockholders: Julian C. Baker

ACADIA PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: Julian C. Baker”): 125,520,719 for, 15,262,794 withheld, per its Form 8-K filed May 29, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 89% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 86 asset managers below reported 32,438,880 for, 8,304,428 withheld.

Showing the 25 largest of 86 asset managers. See all 86 in the interactive database.

Description as filed by funds: To elect three Class II directors to hold office until the Company's 2027 Annual Meeting of Stockholders: Daniel B. Soland

ACADIA PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: Daniel B. Soland”): 124,834,854 for, 15,948,659 withheld, per its Form 8-K filed May 29, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 89% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 85 asset managers below reported 33,416,236 for, 7,267,072 withheld.

Showing the 25 largest of 85 asset managers. See all 85 in the interactive database.

Description as filed by funds: To elect three Class II directors to hold office until the Company's 2027 Annual Meeting of Stockholders: Stephen R. Biggar, M.D., Ph.D.

ACADIA PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: Stephen R. Biggar, M.D., Ph.D.”): 128,641,034 for, 12,142,479 withheld, per its Form 8-K filed May 29, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 91% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 85 asset managers below reported 35,395,284 for, 5,288,024 withheld.

Showing the 25 largest of 85 asset managers. See all 85 in the interactive database.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice). The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.

Fund voting reports, all 83 managers: 36,323,634 for, 4,173,102 against. Showing the 25 largest; see all in the interactive database.

Institutional-manager reports, all 3 managers: 2,422,610 for.

Description as filed by funds: To approve, on an advisory basis, the compensation of the Company's named executive officers, as disclosed in this proxy statement.

ACADIA PHARMACEUTICALS INC.’s own tally for this item (“the approval, on an advisory basis, of the compensation of the Company's named executive officers, as disclosed in the Proxy Statement, which was approved by the following vote”): 132,994,018 for, 7,639,777 against — passed, per its Form 8-K filed May 29, 2024 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “In addition to the election of three Class II directors, the following matters were submitted to a vote of the stockholders at the 2024 Annual Meeting: (i) the approval, on an advisory basis, of the compensation of the Company's named executive officers, as disclosed in the Proxy Statement, which w…”
Support: 95% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports, all 84 managers: 39,300,296 for, 1,185,753 against, 12,690 abstained. Showing the 25 largest; see all in the interactive database.

Institutional-manager reports, all 247 managers: 103,475,771 for, 6,307,343 against, 500 abstained, 1,545 not voted. Showing the 25 largest; see all in the interactive database.

Description as filed by funds: TO RATIFY THE SELECTION OF ERNST & YOUNG LLP AS THE COMPANY'S INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE FISCAL YEAR ENDING DECEMBER 31, 2024.

ACADIA PHARMACEUTICALS INC.’s own tally for this item (“the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2024, which was ratified by the following vote”): 150,018,775 for, 988,631 against — passed, per its Form 8-K filed May 29, 2024 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “(iii) the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2024, which was ratified by the following vote:”
Support: 99.3% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 85 asset managers below reported 40,727,527 for, 1,088 against, 12,690 abstained.

Showing the 25 largest of 85 asset managers. See all 85 in the interactive database.